Evofem Biosciences
Evofem Biosciences, Inc. (NASDAQ: EVFM) is a women's health pharmaceutical company focused on developing and commercializing innovative products that address serious unmet needs in sexual and reproductive health. According to its website at evofem.com, the company developed Phexxi — the first and only FDA-approved, hormone-free, on-demand contraceptive gel for women — which provides women seeking to avoid pregnancy with a non-hormonal, prescription contraceptive option that works at the time of use rather than requiring daily adherence to a hormonal regimen. Phexxi is a vaginal gel that maintains the vaginal pH at a level that inhibits sperm motility and viability, providing contraceptive efficacy through a biological mechanism entirely distinct from hormonal contraceptives, IUDs, or barrier methods, offering women a new category of contraceptive choice that supports reproductive autonomy without hormonal side effects.
Evofem's commercial product Phexxi, described at evofem.com, was FDA-approved in 2020 and is prescribed by healthcare providers and available at pharmacies nationwide, with the company building its commercial presence through a specialty sales force focused on OB/GYN and other women's health providers who prescribe contraception. Phexxi's hormone-free mechanism makes it a particularly attractive option for women who cannot or prefer not to use hormonal contraceptives — a significant population that includes women with certain medical conditions, those who experience adverse side effects from hormonal methods, or those who simply prefer the autonomy and flexibility of an on-demand product they use only when needed for contraception. The Phexxi contraceptive gel is used vaginally within one hour prior to each act of intercourse, providing per-encounter contraceptive protection without the systemic effects of hormone-based methods.
Evofem Biosciences has also investigated the potential of Phexxi's vaginal pH-modifying mechanism for sexually transmitted infection prevention, with a Phase 2/3 clinical trial evaluating the product's potential to reduce the risk of chlamydia and gonorrhea transmission — a substantial additional market opportunity if efficacy in STI prevention can be demonstrated and regulatory approval obtained. According to evofem.com, the company's strategy centers on establishing Phexxi as a leading hormone-free contraceptive brand while advancing its clinical pipeline in women's sexual health. Evofem's combination of the first hormone-free on-demand prescription contraceptive, growing commercial awareness among women's health prescribers, and pipeline development in STI prevention positions it as a distinctive and mission-driven participant in the women's reproductive health pharmaceutical market.